MXPA06014083A - Estructura cristalina de dipeptidil peptidasa iv y usos de la misma. - Google Patents

Estructura cristalina de dipeptidil peptidasa iv y usos de la misma.

Info

Publication number: MXPA06014083A
Authority: MX; Mexico
Prior art keywords: dpp; computer; amino acid; seq; listed
Prior art date: 2004-06-03

Application number

MXPA06014083A

Other languages

English (en)

Spanish (es)

Inventor

Xiayang Qiu

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-03

Filing date

2005-05-26

Publication date

2007-02-15

2005-05-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-02-15 Publication of MXPA06014083A publication Critical patent/MXPA06014083A/es

Links

101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 title claims abstract description 140
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 title claims abstract description 138
239000013078 crystal Substances 0.000 title claims abstract description 51
239000003446 ligand Substances 0.000 claims abstract description 71
108090000623 proteins and genes Proteins 0.000 claims abstract description 56
102000004169 proteins and genes Human genes 0.000 claims abstract description 38
238000012545 processing Methods 0.000 claims abstract description 21
238000000034 method Methods 0.000 claims description 78
108090000765 processed proteins & peptides Proteins 0.000 claims description 64
102000004196 processed proteins & peptides Human genes 0.000 claims description 62
150000001413 amino acids Chemical class 0.000 claims description 59
229920001184 polypeptide Polymers 0.000 claims description 57
125000003275 alpha amino acid group Chemical group 0.000 claims description 38
230000027455 binding Effects 0.000 claims description 35
239000000203 mixture Substances 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 17
238000013500 data storage Methods 0.000 claims description 17
125000000539 amino acid group Chemical group 0.000 claims description 12
238000002425 crystallisation Methods 0.000 claims description 12
230000008025 crystallization Effects 0.000 claims description 12
238000013461 design Methods 0.000 claims description 11
230000003936 working memory Effects 0.000 claims description 10
238000009510 drug design Methods 0.000 claims description 7
238000005094 computer simulation Methods 0.000 claims description 6
239000011550 stock solution Substances 0.000 claims description 6
239000011232 storage material Substances 0.000 claims description 6
239000000758 substrate Substances 0.000 claims description 6
238000002441 X-ray diffraction Methods 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
238000000502 dialysis Methods 0.000 claims description 4
238000009792 diffusion process Methods 0.000 claims description 4
230000008569 process Effects 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims 2
239000003112 inhibitor Substances 0.000 abstract description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 15
201000010099 disease Diseases 0.000 abstract description 13
235000001014 amino acid Nutrition 0.000 description 53
229940024606 amino acid Drugs 0.000 description 49
210000004027 cell Anatomy 0.000 description 40
239000013598 vector Substances 0.000 description 33
235000018102 proteins Nutrition 0.000 description 31
102000004190 Enzymes Human genes 0.000 description 20
108090000790 Enzymes Proteins 0.000 description 20
229940088598 enzyme Drugs 0.000 description 20
230000014509 gene expression Effects 0.000 description 20
108020004414 DNA Proteins 0.000 description 19
229940079593 drug Drugs 0.000 description 19
239000003814 drug Substances 0.000 description 19
239000000126 substance Substances 0.000 description 17
239000013604 expression vector Substances 0.000 description 16
102000039446 nucleic acids Human genes 0.000 description 16
108020004707 nucleic acids Proteins 0.000 description 16
150000007523 nucleic acids Chemical class 0.000 description 16
241000700605 Viruses Species 0.000 description 12
230000003197 catalytic effect Effects 0.000 description 11
229910052757 nitrogen Inorganic materials 0.000 description 11
208000008589 Obesity Diseases 0.000 description 10
235000020824 obesity Nutrition 0.000 description 10
239000008194 pharmaceutical composition Substances 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
238000003860 storage Methods 0.000 description 10
208000011580 syndromic disease Diseases 0.000 description 10
239000013612 plasmid Substances 0.000 description 9
241000701447 unidentified baculovirus Species 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000013459 approach Methods 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
239000012634 fragment Substances 0.000 description 8
230000006870 function Effects 0.000 description 8
108091033319 polynucleotide Proteins 0.000 description 8
102000040430 polynucleotide Human genes 0.000 description 8
239000002157 polynucleotide Substances 0.000 description 8
238000001890 transfection Methods 0.000 description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
229910052799 carbon Inorganic materials 0.000 description 7
238000000126 in silico method Methods 0.000 description 7
230000003993 interaction Effects 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
125000003729 nucleotide group Chemical group 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
238000013519 translation Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
208000001132 Osteoporosis Diseases 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
239000000556 agonist Substances 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000011575 calcium Substances 0.000 description 6
238000004422 calculation algorithm Methods 0.000 description 6
238000010367 cloning Methods 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000013518 transcription Methods 0.000 description 6
230000035897 transcription Effects 0.000 description 6
208000004476 Acute Coronary Syndrome Diseases 0.000 description 5
241000282414 Homo sapiens Species 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
210000004899 c-terminal region Anatomy 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
238000004590 computer program Methods 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
238000007876 drug discovery Methods 0.000 description 5
239000002609 medium Substances 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
208000010444 Acidosis Diseases 0.000 description 4
208000007848 Alcoholism Diseases 0.000 description 4
208000019901 Anxiety disease Diseases 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
208000010392 Bone Fractures Diseases 0.000 description 4
208000002177 Cataract Diseases 0.000 description 4
208000000094 Chronic Pain Diseases 0.000 description 4
208000007342 Diabetic Nephropathies Diseases 0.000 description 4
208000032131 Diabetic Neuropathies Diseases 0.000 description 4
206010012689 Diabetic retinopathy Diseases 0.000 description 4
206010061818 Disease progression Diseases 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
208000002705 Glucose Intolerance Diseases 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
206010018473 Glycosuria Diseases 0.000 description 4
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 4
208000031226 Hyperlipidaemia Diseases 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
208000031773 Insulin resistance syndrome Diseases 0.000 description 4
206010027417 Metabolic acidosis Diseases 0.000 description 4
208000029725 Metabolic bone disease Diseases 0.000 description 4
108090000189 Neuropeptides Proteins 0.000 description 4
206010049088 Osteopenia Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
206010036049 Polycystic ovaries Diseases 0.000 description 4
208000020221 Short stature Diseases 0.000 description 4
206010049416 Short-bowel syndrome Diseases 0.000 description 4
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 4
-1 alkali metal salts Chemical class 0.000 description 4
230000036506 anxiety Effects 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
208000033679 diabetic kidney disease Diseases 0.000 description 4
230000006806 disease prevention Effects 0.000 description 4
206010015037 epilepsy Diseases 0.000 description 4
206010016256 fatigue Diseases 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000045598 human DPP4 Human genes 0.000 description 4
208000000509 infertility Diseases 0.000 description 4
230000036512 infertility Effects 0.000 description 4
231100000535 infertility Toxicity 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
206010022437 insomnia Diseases 0.000 description 4
208000002551 irritable bowel syndrome Diseases 0.000 description 4
239000003550 marker Substances 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
238000010369 molecular cloning Methods 0.000 description 4
201000010065 polycystic ovary syndrome Diseases 0.000 description 4
201000009104 prediabetes syndrome Diseases 0.000 description 4
238000007670 refining Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000012546 transfer Methods 0.000 description 4
231100000397 ulcer Toxicity 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
208000032781 Diabetic cardiomyopathy Diseases 0.000 description 3
208000030814 Eating disease Diseases 0.000 description 3
208000019454 Feeding and Eating disease Diseases 0.000 description 3
108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 3
102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 3
102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
206010056438 Growth hormone deficiency Diseases 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
208000001145 Metabolic Syndrome Diseases 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
150000005829 chemical entities Chemical class 0.000 description 3
238000007385 chemical modification Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
235000014632 disordered eating Nutrition 0.000 description 3
238000001914 filtration Methods 0.000 description 3
230000035780 glucosuria Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
229960000310 isoleucine Drugs 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
229910021645 metal ion Inorganic materials 0.000 description 3
230000037230 mobility Effects 0.000 description 3
238000000302 molecular modelling Methods 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
238000003259 recombinant expression Methods 0.000 description 3
230000006798 recombination Effects 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
150000003384 small molecules Chemical class 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
102000055025 Adenosine deaminases Human genes 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
101800001415 Bri23 peptide Proteins 0.000 description 2
102400000107 C-terminal peptide Human genes 0.000 description 2
101800000655 C-terminal peptide Proteins 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
239000007993 MOPS buffer Substances 0.000 description 2
102000012750 Membrane Glycoproteins Human genes 0.000 description 2
108010090054 Membrane Glycoproteins Proteins 0.000 description 2
102000003797 Neuropeptides Human genes 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
239000004473 Threonine Substances 0.000 description 2
230000004913 activation Effects 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
235000021229 appetite regulation Nutrition 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
230000003833 cell viability Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000005138 cryopreservation Methods 0.000 description 2
238000002050 diffraction method Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012595 freezing medium Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000015654 memory Effects 0.000 description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000000329 molecular dynamics simulation Methods 0.000 description 2
238000000324 molecular mechanic Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
238000007899 nucleic acid hybridization Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000004088 simulation Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
241000894007 species Species 0.000 description 2
230000000153 supplemental effect Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
IHBAVXVTGLANPI-QMMMGPOBSA-N 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one Chemical compound CC(C)[C@H](N)C(=O)N1CCCC1 IHBAVXVTGLANPI-QMMMGPOBSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
101710129138 ATP synthase subunit 9, mitochondrial Proteins 0.000 description 1
101710168506 ATP synthase subunit C, plastid Proteins 0.000 description 1
101710114069 ATP synthase subunit c Proteins 0.000 description 1
101710197943 ATP synthase subunit c, chloroplastic Proteins 0.000 description 1
101710187091 ATP synthase subunit c, sodium ion specific Proteins 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
108010037255 Member 7 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
241000220010 Rhode Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102100038803 Somatotropin Human genes 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000002457 bidirectional effect Effects 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000005352 clarification Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000002288 cocrystallisation Methods 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000000205 computational method Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000008150 cryoprotective solution Substances 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000014101 glucose homeostasis Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000008991 intestinal motility Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
102000019758 lipid binding proteins Human genes 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000004973 liquid crystal related substance Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
STEPQTYSZVCJPV-UHFFFAOYSA-N metazachlor Chemical compound CC1=CC=CC(C)=C1N(C(=O)CCl)CN1N=CC=C1 STEPQTYSZVCJPV-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000011164 ossification Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
230000036964 tight binding Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
229910052723 transition metal Inorganic materials 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
239000004474 valine Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

MXPA06014083A 2004-06-03 2005-05-26 Estructura cristalina de dipeptidil peptidasa iv y usos de la misma. MXPA06014083A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US57687704P	2004-06-03	2004-06-03
PCT/IB2005/001630 WO2005119526A1 (en)	2004-06-03	2005-05-26	Crystal structure of dipeptidyl peptidase iv (dpp-iv) and uses thereof

Publications (1)

Publication Number	Publication Date
MXPA06014083A true MXPA06014083A (es)	2007-02-15

Family

ID=34969993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA06014083A MXPA06014083A (es)	2004-06-03	2005-05-26	Estructura cristalina de dipeptidil peptidasa iv y usos de la misma.

Country Status (4)

Country	Link
EP (1)	EP1756740A1 (de)
CA (1)	CA2569095A1 (de)
MX (1)	MXPA06014083A (de)
WO (1)	WO2005119526A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CA2810522A1 (en)	2006-05-04	2007-11-15	Boehringer Ingelheim International Gmbh	Polymorphs
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2400976B1 (de) *	2009-02-27	2016-12-14	Trustees Of Tufts College	Sanfte proteasehemmer und pro-sanfte formen
US8716482B2 (en) *	2009-09-25	2014-05-06	Merck Sharp & Dohme Corp.	Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP2366394A1 (de) *	2010-03-17	2011-09-21	IMTM GmbH	Charakterisierung und Validierung von Inhibitoren und Liganden der Dipeptidyl-Aminopeptidase IV (DP IV)
US8980929B2 (en)	2010-05-21	2015-03-17	Merck Sharp & Dohme Corp.	Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
EP2600888A2 (de) *	2010-08-03	2013-06-12	Cadila Pharmaceuticals Ltd.	Neue verbindungen als dpp-iv-inhibitoren und verfahren zu ihrer herstellung
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis

2005
- 2005-05-26 MX MXPA06014083A patent/MXPA06014083A/es unknown
- 2005-05-26 CA CA002569095A patent/CA2569095A1/en not_active Abandoned
- 2005-05-26 EP EP05744309A patent/EP1756740A1/de not_active Withdrawn
- 2005-05-26 WO PCT/IB2005/001630 patent/WO2005119526A1/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2569095A1 (en)	2005-12-15
WO2005119526A1 (en)	2005-12-15
EP1756740A1 (de)	2007-02-28

Publication	Publication Date	Title
US20050075795A1 (en)	2005-04-07	Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase (PDE1B) and uses thereof
WO2005113762A1 (en)	2005-12-01	CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
US20080215249A1 (en)	2008-09-04	Crystallization and structure determination of beta secretase and/or beta secretase-like proteins
Kusano et al.	2008	Crystal structure of the human receptor activity‐modifying protein 1 extracellular domain
MXPA06014083A (es)	2007-02-15	Estructura cristalina de dipeptidil peptidasa iv y usos de la misma.
US20040171019A1 (en)	2004-09-02	PIN1 peptidyl-prolyl isomerase polypeptides, their crystal structures, and use thereof for drug design
US20050202550A1 (en)	2005-09-15	Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase (PDE10A) and uses thereof
Carafoli et al.	2005	Crystal structure of the β‐chain of human hepatocyte growth factor‐like/macrophage stimulating protein
WO2011033322A2 (en)	2011-03-24	Crystal structure
EP1301536B1 (de)	2006-06-07	Modulation der tetraspanin funktion
EP1265927B1 (de)	2009-04-29	Kristall
US20050085626A1 (en)	2005-04-21	Polo domain structure
US20080064052A1 (en)	2008-03-13	Crystal of a Receptor-Ligand Complex and methods of use
AU781654B2 (en)	2005-06-02	Crystallization and structure determination of staphylococcus aureus thymidylate kinase
EP4004925B1 (de)	2025-06-25	Verfahren zur erzeugung von varianten eines proteins
JP2003502036A (ja)	2003-01-21	カスパーゼ−８の結晶、モデルおよび方法
US20060234293A1 (en)	2006-10-19	Polypeptide methods and means
EP4367226A1 (de)	2024-05-15	Kristallstrukturen von alk- und ltk-rezeptortyrosinkinasen und deren liganden
US20080020984A1 (en)	2008-01-24	Crystal Structure of a Receptor-Ligand Complex and Methods of Use
EP1393235A1 (de)	2004-03-03	Kristallisiertes polypeptid der liganden bindungsdomäne des menschlichen xenobiotischen nuklearen rezeptors pxr/sxr sowie dieses verwendende screening-verfahren
EP1618133A1 (de)	2006-01-25	Kristallstukturen von vegfrkd:ligandkomplexen und verfahren zur deren verwendung
MXPA06009940A (en)	2007-04-10	Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase (pde10a) and uses thereof
US20050131209A1 (en)	2005-06-16	Crystallized hnf4 gamma ligand binding domain polypeptide and screening methods employing same
WO2005103241A1 (en)	2005-11-03	Crystal structure of 3', 5'-cyclic nucleotide phosphodiesterase 9a (pde9a) and uses thereof
WO2005119525A1 (en)	2005-12-15	11βHSD1 CRYSTAL STRUCTURES FOR STRUCTURE BASED DRUG DESIGN